Speech-Language Pathologists in Bellefontaine, OH Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Mrs. Amanda Hecker, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1001 Ludlow Rd, Bellefontaine, OH 43311 Phone: 937-599-4331

Hana Elizabeth Fischesser, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 205 Palmer Street, Bellefontaine, OH 43311 Phone: 937-592-4015

Katelynn Paige Hodge, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1101 Ludlow Rd, Bellefontaine, OH 43311 Phone: 937-599-4331

Aisuluu Baatyrbek Kyzy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 509 N Park St, Bellefontaine, OH 43311 Phone: 937-592-5646

Mrs. Tara Lynn Vehorn, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 121 S Opera St, Bellefontaine, OH 43311 Phone: 937-599-5195

Tyler Atwood, MA CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2739 County Road 91, Bellefontaine, OH 43311 Phone: 937-599-7075

Kacie Ross, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 820 Ludlow Rd, Bellefontaine, OH 43311 Phone: 937-593-9060

Julia Quay Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 820 Ludlow Rd, Bellefontaine, OH 43311 Phone: 937-593-9060

News Archive

New highly-accurate blood test can measure all forms of vitamin D deficiencies

Researchers from London's Kingston University have developed a new highly-accurate blood test which can detect how much a patient's diet could be responsible for a lack of the so-called 'sunshine vitamin'. Vitamin D deficiencies can weaken the immune system and increase the risk of cancer and osteoporosis.

Novel vaccine approach appears to protect fetus from CMV infection, animal study shows

Long before the Zika virus became a global fear, cytomegalovirus, or CMV, was commonly infecting developing fetuses and causing many of the same brain and developmental impairments.

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

Liberator Medical Holdings closes private placement of 4.66M common stock shares

Liberator Medical Holdings, Inc. announces today the closing of a private placement of 4,666,667 shares of its common stock for gross proceeds of $7.0 million on March 9, 2010, to a single institutional investor. Littlebanc Advisors, LLC. acted as the sole placement agent and financial advisor to the Company. Liberator's Board of Directors unanimously approved the transaction. As part of the transaction, the institutional investor has the right to add a member of its choice to Liberator Medical's Board of Directors.

Researchers develop guidelines to standardize performance tests for neural interfaces

How can scientists measure and define the performance of neural electrodes if there are no uniform standards? Freiburg microsystems engineer Dr. Maria Asplund together with Dr. Christian Böhler and Prof. Dr. Thomas Stieglitz, as well as Prof. Dr. Luciano Fadiga and Dr. Stefano Carli from the Italian Institute of Technology at the University of Ferrara, Italy, have developed guidelines to standardize the testing of the performance of electrodes for neural interfaces and bioelectronic systems.

Read more Medical News

› Verified 4 days ago